A Study of Cutaneous Adverse Drug Reactions in A Tertiary Care Centre in Central Andhrapradesh, South India
Keywords:Drugs, Cutaneous adverse drug reactions, FDE, Incidence.
Background Cutaneous adverse drug reactions (CADR) are common, accounting 10-30% of reported adverse drug reactions. Severe and potentially life-threatening reactions may occur in approximately 1 in 1000 hospital patients. There is a spectrum of cutaneous adverse drug reactions varying from transient maculopapular rash to fatal toxic epidermal necrolysis (TEN).The most common morphological types of cutaneous ADRs range from maculopapular, urticaria/angioedema to fixed drug eruptions, and the common incriminating drug groups remain antimicrobials, anticonvulsants and non-steroid anti-inflammatory drugs (NSAIDS). Aims: To determine the prevalence of cutaneous adverse drug reactions among the patients attending KIMS, Amalapuram. Methods: Type of study: The study is a hospital based cross sectional study.
Duration: December 2018 - September 2020. Place:This study was conducted in Konaseema institute of medical sciences and research foundation & research foundation, Amalapuram, East Godavari, and Andhra Pradesh. Method of collection:Data will be collected after obtaining informed/written consent from the patient. Detailed history, clinical examination and relevant laboratory investigations will be done. The data will be entered into a case record form specially designed for the study and statistical analysis will be done. Results:In our Study 0.17% was the overall incidence of Cutaneous drug reactions during this period found in this study,females are outnumbered, The most common cutaneous adverse drug reactions were FDE 58 (46.77), followed by Maculopapular Drug Rash 18 (14.51%), Acneiform Eruption 10 (8.06%).Conclusion: The overall incidence in this study was 0.17%.
How to Cite
Copyright (c) 2022 Sappa Ramatulasi, Kirankanth Vudayana, Manipati Shruthi, Akhila Sri Vedala, Sruthi Kandimalla
This work is licensed under a Creative Commons Attribution 4.0 International License.